PRECISION 1: A phase 2, multicenter, open-label basket trial of nab -sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 .

Gopa Iyer,David J. Kwiatkowski,Li Ding,Anita N. Schmid,Willis H. Navarro,Jordi Rodon Ahnert

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.tps526

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:TPS526 Background: According to SEER data, patients in the USA with advanced genitourinary (GU) cancers such as bladder and kidney cancers have low 5-year survival rates of 8.3% and 17.8%, respectively. This underscores the need for more efficacious treatments. Tumor growth and disease progression may be facilitated by aberrant activation of the mTOR pathway in some GU cancers. The tumor suppressor genes TSC1 and TSC2 are critical negative regulators of the mTOR pathway, and their inactivation may result in tumor growth. Inactivating TSC1 and TSC2 alterations have been observed in GU cancers with combined frequencies of up to 9.6% in bladder, 5.8% in kidney, and 0.7% in prostate cancers. nab-Sirolimus, approved in the USA for patients with advanced malignant perivascular epithelioid cell tumor (PEComa), is an albumin-bound mTOR inhibitor (mTORi) that inhibits the mTOR pathway via suppression of the mTORC1 complex. Clinically, in an exploratory analysis of AMPECT (NCT02494570), a pivotal trial of nab-sirolimus in advanced malignant PEComa, 8/9 (89%) and 1/5 (20%) patients with inactivating alterations in TSC2 and TSC1, respectively, had a confirmed response. Most treatment-related adverse events in AMPECT were grade 1/2 (none were grade ≥4) and were consistent with mTORi-class adverse events. Based on the clinical observations from AMPECT and the underlying mechanism of action of nab-sirolimus, the PRECISION 1 trial was designed to assess the safety and efficacy of nab-sirolimus in a tumor-agnostic study of patients with advanced cancers harboring TSC1 or TSC2 inactivating alterations. Enrollment is open to patients with bladder, kidney, and prostate cancers with TSC1 or TSC2 inactivating alterations. Methods: In PRECISION 1 (NCT05103358), eligible patients are ≥12 years old and mTORi-naïve, have advanced malignant solid tumors with TSC1 or TSC2 inactivating alterations identified using next-generation sequencing (NGS) in tumor tissue or liquid biopsy (confirmed by central review of NGS reports), and they have received appropriate standard treatments, per investigator. nab-Sirolimus 100 mg/m 2 will be given intravenously over 30 min on days 1 and 8 of each 21-day cycle. The primary endpoint is overall response rate per independent radiographic review (IRR) using Response Evaluation Criteria in Solid Tumors v1.1. Other endpoints include duration of response, time to response, progression-free survival by IRR, overall survival, patient-reported quality of life, and safety. Enrollment began in March 2022. Collaboration with leading NGS vendors will expedite the identification of patients with qualifying TSC1 and TSC2 alterations; ongoing study access is facilitated through a just-in-time approach to trial location activation. Clinical trial information: NCT05103358 .

oncology